Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
Ionis Pharmaceuticals Inc IONS
News
IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ionis Pharmaceuticals (IONS)
A failed trial for a heart drug casts shadow over rivals developing similar therapies
Ionis reports third quarter 2026 financial results and highlights progress on key programs
Ionis to hold third quarter 2026 financial results webcast
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Ionis ranked #1 on Science’s Top Employers list
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
Novartis's failed trial for cholesterol drug leads to broad biopharma stock selloff
Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint — 2nd Update
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint — Update
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
Ionis to present at upcoming investor conferences
United States